Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7829960 | 0.81 | HDAC2 (0.45) | HDAC2MAP4K4ABL1MAPK8CSNK1A1 | |
| SCHEMBL16693061 | 0.77 | HDAC2 (0.45) | HDAC2MAP4K4ABL1MAPK8CSNK1A1 | |
| SCHEMBL15939967 | 0.76 | HDAC2 (0.61) | HDAC2MAP4K4ABL1MAPK8CSNK1A1 | |
| SCHEMBL15939968 | 0.76 | HDAC2 (0.61) | HDAC2MAP4K4ABL1MAPK8CSNK1A1 | |
| SCHEMBL25372696 | 0.74 | DRD2 (0.35) | — | |
| SCHEMBL25370113 | 0.74 | DRD2 (0.38) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL212085 | 0.73 | MAP4K4 (0.58) | HDAC2MAP4K4ABL1MAPK8CSNK1A1 | |
| SCHEMBL14831925 | 0.73 | DRD2 (0.44) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL25373314 | 0.70 | DRD2 (0.36) | NPC1KDM4EPKMHSD17B10ALDH1A1 | |
| SCHEMBL25372062 | 0.70 | CYP11B2 (0.33) | KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-110511253-B | Synthesis method of On-DNA tetrahydro-beta-carboline compound in construction of DNA coding compound library | 上海药明康德新药开发有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4549442-A1 | PRMT5 INHIBITORS AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| EP-4549440-A1 | CLASS OF PRMT5 INHIBITORS AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-119775261-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250074922-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-03-06 | — | — | US | disclosed |
| CN-119562954-A | PRMT5 inhibitor and application thereof | 上海赛岚生物科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
| US-20140051680-A1 | Histone Deacetylase Inhibitors | REPLIGEN CORPORATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051680-A1 | Histone Deacetylase Inhibitors | REPLIGEN CORPORATION (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2013045516-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-04-04 | — | — | WO | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | HDAC2 130/4885MAP4K4 2877/4885ABL1 874/4885 |
| US-20140051680-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC3 | HDAC2 2/4885MAP4K4 1744/4885ABL1 4366/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | HDAC2 211/4885MAP4K4 1602/4885ABL1 1147/4885 |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | HDAC2 980/4885MAP4K4 2677/4885ABL1 304/4885 |
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | HDAC2 187/4885MAP4K4 3088/4885ABL1 2530/4885 |
| US-20250074922-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | HDAC2 3394/4885MAP4K4 2086/4885ABL1 308/4885 |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | HDAC2 309/4885MAP4K4 2620/4885ABL1 2094/4885 |
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | PRMT5, PRMT1, PRMT6 | HDAC2 96/4885MAP4K4 1599/4885ABL1 600/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | HDAC2 3335/4885MAP4K4 2392/4885ABL1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.